Managing Severe and Persistent Pain

Xtampza ER is an extended-release opioid analgesic appropriate for the management of pain that is severe enough to require daily, around-the-clock, long-term treatment. It is intended for use in patients for whom alternative treatments, such as non-opioid medications, have been found inadequate or ineffective. The medication is generally reserved for individuals experiencing chronic pain conditions, including specific types of long-term illness-related discomfort or pain stemming from certain chronic injuries.

Xtampza ER's benefit is supporting patient comfort by providing relief from the intensity and frequency of severe pain flares throughout the day and night. This consistent relief is crucial for managing conditions that require a steady analgesic presence. The medication is used for severe, persistent, and chronic pain.

“Consistent pain management is a key component in supporting the quality of life for patients with severe chronic conditions.”

Xtampza ER (oxycodone extended-release) is an opioid analgesic restricted to use in patients for whom alternative treatment options are inadequate and who require daily, around-the-clock, long-term treatment. Its use is defined by strict regulatory exclusions and limitations based on specific patient populations and conditions.

---

Contraindications (Who Must Not Use)

Xtampza ER is contraindicated in patients with the following life-threatening conditions:

• Significant respiratory depression or acute/severe bronchial asthma in an unmonitored setting.
• Known or suspected gastrointestinal obstruction, including paralytic ileus.
• Known hypersensitivity to oxycodone or any component of the product.

---

Population-Specific Limitations

Population	Regulatory Status
Pediatric Use	Not approved; safety and efficacy have not been established. Accidental ingestion, especially by children, can be fatal.
Pregnancy	May cause fetal harm. Prolonged maternal use can result in Neonatal Opioid Withdrawal Syndrome (NOWS).
Lactation	Not recommended, as oxycodone passes into breast milk.
Hepatic or Renal Impairment	Restricted use; initiation requires a reduced dosage and careful monitoring for adverse effects.
Opioid Tolerance	Doses above 72 mg total daily dose are only for use in patients in whom opioid tolerance has been established.

Interactions with other medicines and products

The use of Xtampza Er (oxycodone extended-release) with certain other medicines or substances can lead to serious risks, including profound sedation, respiratory depression, coma, and death. These interactions are primarily tied to two mechanistic categories: additive CNS depression and altered oxycodone metabolism.

Major Interacting Drug Categories

Interacting Product Category	Key Interaction Concern	Regulatory Guidance
CNS Depressants (including alcohol, benzodiazepines, other opioids)	Profound sedation, respiratory depression, coma, and death due to additive effects.	Reserve co-prescribing for inadequate alternatives; limit dosages and duration.
CYP3A4 Inhibitors (e.g., specific antifungals or antibiotics)	Increased oxycodone plasma concentration, which can cause fatal overdose and prolonged adverse effects.	Monitor closely; consider a dose reduction of Xtampza Er.
CYP3A4 Inducers (e.g., specific anticonvulsants or rifampin)	Discontinuation of an inducer may lead to a subsequent, rapid increase in oxycodone plasma levels and overdose risk.	Monitor closely; dose adjustments may be needed upon initiation or discontinuation.
Serotonergic Drugs (e.g., SSRIs, SNRIs, triptans)	Risk of Serotonin Syndrome, a potentially life-threatening condition.	Discontinue Xtampza Er if Serotonin Syndrome is suspected.
MAO Inhibitors (MAOIs)	Can potentiate the effects of oxycodone.	Avoid concomitant use or within 14 days of stopping MAOI treatment.
Mixed Agonist/Antagonist Opioids (e.g., butorphanol, nalbuphine)	May reduce the analgesic effect or precipitate opioid withdrawal symptoms.	Avoid use.

Alcohol (Ethanol) is specifically listed as a CNS depressant that must be avoided during treatment due to the substantial risk of fatal respiratory depression. Any required coadministration of Xtampza Er with other CNS depressants necessitates the use of the lowest effective doses and close patient monitoring for signs of sedation and breathing difficulties.

Xtampza ER's active agent, oxycodone, functions as a mu-opioid receptor ( MOR) agonist in the central nervous system and peripheral tissues. The MOR is a G protein-coupled receptor ( GPCR) primarily coupled to the inhibitory Gi protein. Oxycodone binding stimulates the Gi subunit to inhibit adenylyl cyclase activity, which decreases the intracellular concentration of cyclic adenosine monophosphate ( cAMP).

Downstream signaling cascades involve two key actions: Gi activation directly leads to the opening of G protein-coupled inwardly rectifying potassium channels ( GIRKs) and the inhibition of N-type voltage-gated calcium channels ( VGCCs). The opening of GIRKs causes potassium efflux and neuronal hyperpolarization (post-synaptic inhibition), making the neuron less excitable. The inhibition of pre-synaptic VGCCs reduces the influx of calcium ions, consequently decreasing the release of various pronociceptive neurotransmitters, such as substance P and glutamate, into the synaptic cleft.

This combined pre- and post-synaptic inhibition modulates neuronal activity in ascending pain pathways (e.g., the dorsal horn of the spinal cord and periaqueductal gray). System-level physiological consequences include generalized central nervous system depression, decreased gastrointestinal motility, and suppression of the medullary respiratory center.

Administration Guidelines for Xtampza ER

Xtampza ER is an extended-release capsule intended for consistent, around-the-clock management of persistent, severe pain. Dose, frequency, and administration method are designed to maintain the integrity of its extended-release properties.

---

Administration Scope

Instruction	Detail
Route of Administration	Oral administration.
Dosing Schedule	The initial dose for opioid-naïve adults is 9 mg administered every 12 hours. Doses are adjusted gradually (titrated) by a healthcare professional every three to seven days until a stable, effective dose is achieved. It is intended for long-term use, not for as-needed treatment.
Timing in relation to meals	Must be taken with food to ensure consistent drug absorption and predictable plasma exposure.
Preparation Requirements	The capsule is available in strengths from 9 mg to 36 mg. It can be taken as an intact capsule, or the entire contents may be sprinkled onto soft food (like applesauce) or suspended in water for feeding tube delivery.
Special Procedural Conditions	The capsule or its contents must not be crushed, dissolved, or chewed under any circumstances. If the contents are sprinkled for immediate use, they must be swallowed right away.

---

Population and Discontinuation Rules

For patients with hepatic impairment, the starting dose is reduced to one-third to one-half of the usual dosage, followed by careful titration. If a dose is missed, the patient should take the next scheduled dose at the usual time and should not take an extra dose. Furthermore, therapy is gradually tapered when discontinuing use in physically-dependent patients to mitigate withdrawal effects.

Research Evidence / Overview of Studies for Xtampza Er

---

Evidence for Use in Managing Severe and Persistent Pain

This section outlines the research that has evaluated Xtampza Er was evaluated in research involving chronic pain, which is often a condition marked by functional limitations and where symptoms may vary in intensity. The majority of the studies research examined how Xtampza Er was evaluated in settings involving the continuous administration was studied for outcomes related to physical discomfort in people with chronic, severe pain, such as chronic lower back pain.

Clinical trials research explored the use of Xtampza Er against a placebo (an inactive substance) in patients who were already experiencing pain. These studies were applied in research contexts involving fluctuating or unstable symptoms and used in studies examining symptom intensity or variability. The main clinical trials studies monitored outcomes related to physical discomfort across treatment groups receiving Xtampza Er and those receiving a placebo, and studies report how symptoms evolved in the observed populations when compared to those taking an inactive treatment over the defined time intervals. These findings help contextualize how patients reported their experience during the study period.

However, it is important to understand the limits of this evidence. The results apply only to the populations studied, and the initial trials focused mainly on short-term changes. Research provides context but not individual predictions, and research does not determine whether an individual will respond similarly. Comparative evidence is lacking for many direct comparisons against all other similar long-acting pain medications.

---

Long-term Studies and Follow-up

Studies that focus on long-term effects research describe patient experiences and pain outcomes related to systemic or functional imbalance over a longer duration, often months or years. These follow-up studies were observed in patients who continued treatment after initial clinical trials to see how their outcomes reflecting daily functioning or activity level evolved over time. The evidence contributes to understanding symptom patterns when Xtampza Er was studied for extended periods. Studies report how symptoms evolved in the observed populations, allowing researchers to track data show patterns related to outcomes over longer time intervals. This part of the research provides insight into patient-reported outcomes describing perceived discomfort within the evidence derived from settings with varying symptom burdens.

Despite this, long-term effects are not fully established. The follow-up durations were limited in some key studies. The certainty remains low regarding specific outcomes linked to inflammatory or irritative states over a very long duration, and data are still emerging from ongoing observational settings.

---

Evidence in Special Populations

This section summarizes what research examined for Xtampza Er when used by people who might process medication differently due to age or other health factors. Studies monitored the medication's performance in older adults, and those who have pre-existing health conditions marked by functional limitations, specifically issues with the kidneys or liver. For patients with impaired liver or kidney function, studies applied in research contexts involving fluctuating or unstable symptoms suggest that research describes data show patterns related to drug exposure in these groups. The evidence highlights what is known—and what is still uncertain—in these groups.

Evidence is limited for younger populations or populations related to pregnancy. Comparative evidence is lacking for many special populations, and often the sample sizes were modest, meaning the ability to generalize the findings describe patterns observed in the studies is restricted.

---

What is Still Uncertain About Xtampza Er

Transparency about research limitations is crucial. This section summarizes the main areas where more research is needed or where findings have been inconsistent. One key area is that comparative evidence is lacking for many direct comparisons against other similar pain medications in terms of long-term patient-reported outcomes describing perceived discomfort. Evidence quality varies across studies, and findings were mixed in some research regarding specific metrics or patient types. The long-term observation on outcomes related to systemic or functional imbalance is an area where certainty remains low.

Ultimately, research is ongoing to address these uncertainties. Studies contribute to the broader evidence landscape, but until those studies are completed, there is limited information for long-term outcomes and for certain understudied patient groups.

Key Studies & References The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment

Common questions about Xtampza Er (FAQ)

---

Q: What is the difference between Xtampza ER and other long-acting oxycodone medicines?

A: According to official product information, Xtampza ER is an extended-release formulation that incorporates an Abuse-Deterrent Formulation (ADF) technology. The FDA has acknowledged this ADF as a measure intended to make abuse, particularly via injection and other forms of physical manipulation, difficult. This specialized formulation is the primary feature that differentiates it from other long-acting oxycodone products.

Q: Is Xtampza ER recommended for patients new to opioid treatment?

A: Regulatory documents provide an initial starting dose specifically for opioid-naïve and opioid non-tolerant patients. However, the limitations of use state that this class of drug is only for use in patients whose alternative treatment options, such as non-opioid pain relievers or immediate-release opioids, are inadequate, not tolerated, or otherwise insufficient for severe pain.

Q: Can Xtampza ER be taken by elderly patients?

A: Official labeling describes that for the elderly population, initiation often involves starting at the lower end of the dosage range. This group is noted to have an increased risk of respiratory depression (slowed or shallow breathing) and requires close monitoring, especially when starting the medication.

Q: Can I take over-the-counter pain relievers like Tylenol or Advil with Xtampza ER?

A: Official drug documents issue strong warnings against combining Xtampza ER with certain central nervous system (CNS) depressants, such as alcohol or benzodiazepines, due to the risk of profound sedation and breathing problems. However, the label does not specifically list or exclude common, non-opioid over-the-counter pain relievers such as acetaminophen (Tylenol) or ibuprofen (Advil).

Q: How long does it take for the pain relief from Xtampza ER to start working?

A: The extended-release feature is designed to provide sustained, around-the-clock pain relief over a long period. Pharmacokinetic studies, which measure the drug's absorption rate, indicate that the time to reach maximum concentration ( T max) of the intact capsule is approximately 4.5 hours.

Q: What is the timeframe for the extended-release action of Xtampza ER?

A: The official dosing schedule defines the targeted duration for the extended-release action. Xtampza ER is typically prescribed for administration every 12 hours, meaning the extended-release formulation is designed to provide continuous pain management throughout that 12-hour period.

Q: Does Xtampza ER affect driving or operating machinery?

A: The official label includes a warning that the drug may impair the mental or physical abilities required to perform potentially hazardous activities, such as driving a car or operating machinery. This warning is especially relevant before the medication's effects are stabilized.

Q: Is Xtampza ER safe for patients with a history of head injuries?

A: Official warnings describe that opioids can complicate conditions like a history of head injury, brain tumors, or increased pressure inside the skull. The label notes that opioids can obscure the physical signs of these conditions.

Q: Does Xtampza ER affect sleep?

A: The common adverse reactions observed in clinical studies include somnolence (sleepiness or drowsiness). This is a known effect of the medication that can affect a person's wakefulness and general alertness.

Q: Does Xtampza ER have the potential to cause hormonal changes?

A: Official warnings describe that prolonged opioid use may cause adrenal insufficiency in some patients, especially after taking the medication for a month or longer. This condition involves the body producing low levels of important adrenal hormones.

Q: Does the body develop a tolerance to Xtampza ER over time?

A: Official documentation implies that opioid tolerance may develop over time. The regulatory criteria for higher strengths of the medication specify that these doses are to be reserved only for patients in whom tolerance to an opioid of comparable potency has already been established.

Q: Can Xtampza ER affect a person's mood or cause depression?

A: While the list of common side effects focuses on physical effects like drowsiness and dizziness, regulatory adverse reaction reports include other mood-related effects such as anxiety and irritability observed in clinical studies.

Q: Is it possible to become physically dependent on Xtampza ER without being addicted?

A: Official labeling addresses both physical dependence and addiction as distinct but related issues. Physical dependence is described as a physiological adaptation of the body that requires gradual tapering of the dose upon discontinuation, whereas addiction is addressed separately as a primary warning involving compulsive use and potential harm.

Q: What is the difference between a side effect and a warning for Xtampza ER?

A: Regulatory documents typically separate drug risks into two categories. Adverse Reactions (or side effects) list common, expected patient experiences like nausea and headache. Warnings and Precautions describe serious, potentially life-threatening risks, such as respiratory depression and abuse, that require urgent attention.

Q: Why might a doctor switch a patient from another opioid to Xtampza ER (descriptive only)?

A: The primary differentiating feature of this drug is its Abuse-Deterrent Formulation (ADF). The physical resistance to manipulation, such as crushing or dissolving, provides a factual basis for why this drug may be selected by a prescriber over an opioid formulation lacking this feature.

Q: Can Xtampza ER be used for fibromyalgia pain (informational only)?

A: The drug is indicated for the management of pain severe enough to require long-term, around-the-clock opioid treatment. While clinical trials may focus on conditions such as chronic lower back pain, the indication is not limited to or excluded from use in specific chronic pain syndromes.

Q: Is Xtampza ER used for cancer-related pain?

A: The indication for Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. This broad criteria allows for its use in various conditions, including cancer-related pain, which often requires continuous, severe pain management.

Q: Are there specific age limits for who can use Xtampza ER?

A: Yes, official information states that Xtampza ER is not approved for pediatric use, as its safety and effectiveness have not been established in children. Special considerations and lower starting doses are also described for the elderly population.

Storage and Disposal of Xtampza ER

Xtampza ER must be stored securely, out of sight and reach of children, as accidental ingestion of even one dose can be fatal. The medication is required to be kept at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), and must be stored in its original container to protect it from moisture.

Disposal Requirements

Because of the risk of misuse and accidental overdose, unused or expired Xtampza ER should be disposed of by utilizing a drug take-back program. If a take-back option is not readily available, the medication must be promptly flushed down the toilet. The empty capsule shell remaining after administration must also be flushed right away.